More than 900 US medical cannabis dispensaries have become the first operators in the country to hold federal registration, marking the first tangible change for operators since April’s partial rescheduling order.
As the federal campaign to clamp down on intoxicating hemp in the US rolls on, the Drug Enforcement Administration (DEA) has officially designated hexahydrocannabinol (HHC) a Schedule I substance.
As the industry’s (more than justified) excitement over last week’s rescheduling announcement begins to subside, the regulatory reality is settling in.
After years of false starts, political delays and administrative paralysis, the United States federal government has taken its first concrete step toward rescheduling cannabis.
Cannabis stocks have once again been sent flying in the wake of the latest hint of progress on cannabis rescheduling from Trump’s White House.
Terrance Cole, has been confirmed as the new permanent head of the Drug Enforcement Administration (DEA), and will now be responsible for the future of the landmark cannabis rescheduling project.
The frozen US cannabis rescheduling process appears to be stuck in limbo for the foreseeable future, as the Drug Enforcement Administration’s (DEA’s) new management confirmed the process ‘remains pending’.
Cannabis rescheduling was thrown back into the spotlight last week as the new potential head of the Drug Enforcement Administration (DEA) said it would be a ‘priority’.
A coalition of pro-cannabis medical professionals has dropped its lawsuit against the Drug Enforcement Administration (DEA), clearing one of the many hurdles preventing the process from progressing.
